“'We are entering a new phase'...with a burst of 'potentially curative' drugs that are 'much more expensive,'” CP3 Director Dr. Walid Gellad told The Hill. He explained that the issue is complex because prices need to be high enough to encourage innovation, yet no one can agree on an acceptable profit.